Clinical Trial Update: A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and therapeutic activity of RO6874281 in combination with pembrolizumab for advanced or metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• RO6874281

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Metastatic Melanoma | Phase 1 | Status: COMPLETED